Coherus Biosciences Stock Filter Stocks by Fundamentals
| CHRS Stock | USD 1.26 0.02 1.56% |
Coherus BioSciences fundamentals help investors to digest information that contributes to Coherus BioSciences' financial success or failures. It also enables traders to predict the movement of Coherus Stock. The fundamental analysis module provides a way to measure Coherus BioSciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Coherus BioSciences stock.
Coherus | Shares Owned by Institutions |
Coherus BioSciences Current Valuation Drivers
We derive many important indicators used in calculating different scores of Coherus BioSciences from analyzing Coherus BioSciences' financial statements. These drivers represent accounts that assess Coherus BioSciences' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Coherus BioSciences' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.3B | 1.2B | 1.2B | 614.8M | 313.6M | 518.3M | |
| Enterprise Value | 1.3B | 1.1B | 1.2B | 1.0B | 691.5M | 539.3M |
Coherus BioSciences Institutional Holders
Institutional Holdings refers to the ownership stake in Coherus BioSciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Coherus BioSciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Coherus BioSciences' value.| Shares | Cm Management, Llc | 2024-09-30 | 2 M | Cam Group Holding A/s | 2024-09-30 | 1.9 M | Tejara Capital Ltd | 2024-06-30 | 1 M | Charles Schwab Investment Management Inc | 2024-09-30 | 964.3 K | Los Angeles Capital Management Llc | 2024-09-30 | 930.1 K | Macquarie Group Ltd | 2024-06-30 | 900 K | Northern Trust Corp | 2024-09-30 | 896.7 K | Hudson Bay Capital Management Lp | 2024-09-30 | 785 K | Clearline Capital Lp | 2024-09-30 | 784.4 K | Blackrock Inc | 2024-06-30 | 11.8 M | Vanguard Group Inc | 2024-09-30 | 11.3 M |
Coherus Fundamentals
| Return On Equity | -16.57 | ||||
| Return On Asset | -0.14 | ||||
| Profit Margin | (0) % | ||||
| Operating Margin | (0.09) % | ||||
| Current Valuation | 317.35 M | ||||
| Shares Outstanding | 115.21 M | ||||
| Shares Owned By Insiders | 1.39 % | ||||
| Shares Owned By Institutions | 70.09 % | ||||
| Number Of Shares Shorted | 33.04 M | ||||
| Price To Earning | 4.22 X | ||||
| Price To Book | 73.19 X | ||||
| Price To Sales | 0.48 X | ||||
| Revenue | 257.24 M | ||||
| Gross Profit | (58.4 M) | ||||
| EBITDA | (193.94 M) | ||||
| Net Income | (237.89 M) | ||||
| Cash And Equivalents | 275.48 M | ||||
| Cash Per Share | 3.54 X | ||||
| Total Debt | 480.84 M | ||||
| Current Ratio | 3.17 X | ||||
| Book Value Per Share | (0.76) X | ||||
| Cash Flow From Operations | (174.88 M) | ||||
| Short Ratio | 12.34 X | ||||
| Earnings Per Share | (0.09) X | ||||
| Target Price | 6.5 | ||||
| Number Of Employees | 235 | ||||
| Beta | 0.69 | ||||
| Market Capitalization | 145.17 M | ||||
| Total Asset | 629.6 M | ||||
| Retained Earnings | (1.58 B) | ||||
| Working Capital | 143.86 M | ||||
| Current Asset | 197.39 M | ||||
| Current Liabilities | 106.02 M | ||||
| Net Asset | 629.6 M |
About Coherus BioSciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Coherus BioSciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Coherus BioSciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Coherus BioSciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Coherus Stock Analysis
When running Coherus BioSciences' price analysis, check to measure Coherus BioSciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Coherus BioSciences is operating at the current time. Most of Coherus BioSciences' value examination focuses on studying past and present price action to predict the probability of Coherus BioSciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Coherus BioSciences' price. Additionally, you may evaluate how the addition of Coherus BioSciences to your portfolios can decrease your overall portfolio volatility.